Protocol Design, Compliance, and Feasibility of Frequent Remote Monitoring in Patients Receiving Lecanemab
Preliminary results indicate that frequent remote cognitive testing of AD patients receiving lecanemab is feasible. Compliance appears to be moderate with 61% of participants remaining enrolled 3 months after their first visit. We propose remote monthly assessments as a new model to monitor patients receiving DMTs for AD.
Authors
- Alexa N. Goldstein
- Raseeka O’Chander
- Neguine Rezaii (ORCID: https://orcid.org/0000-0002-8967-9237)
- Mark C. Eldaief
- Brad C. Dickerson
- Erin Anita Krahn
- Scott M McGinnis
- Bonnie Wong
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70858_106208
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00